Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (2594)	11/2/1997 11:31:00 AM
From: JOHN W.	Read Replies (3) \| Respond to of 6136

Subject: Re: Accelerating Sales Date: Sat, Nov 1, 1997 17:04 EST From: Biorich23 Message-id: <19971101220401.RAA17904@ladder01.news.aol.com> 70 by nov. As many who followed the TA of AGPH there was a pattern that developed that had AGPH proceeding to the 70 level by mid-NOV. Re what happened to that pattern was clear. A global stock mkt crash was not factored in, so I hope you understand this. Actually the stock has held up very well and will likely rebound as long as the mkt recovers and moves higher throughout the year. Agouron is likely to see new highs if the mkt rallys because fundamentally we are in a stronger position: 1) We are closer to European Approval as the end of the year approaches. 2) Sales have never been stronger and the more states that approve Viracept only has a jump effrect on this growth: search.main.yahoo.com 3) I hope you have had the opportunity to watch C-span on AIDS treatment and research today. Since Viracept is actually the sole Protease Inhibitor that is federally recommended for the use of treatment of children, 100% acceptance of Viracept on every formulary is mandated. 4) AG3340 data will be released before the end of the year. I have talked to several oncologist/researchers at the trial sites and the company regarding the results seen thus far which have been very exciting. This MMP inhibitor is far superior to British Biotech's (BBIOY) MMP inhibitor that is still in early clinical trials which has a multi-billion market cap for BBIOY . Based on Viracept alone, AGPH is probably 35-45% undervalued. I don't know how you can add a 2B mkt cap biotech value to AGPH based on their MMP inhibitor as BBIOY since they are actually a profitable pharmaceutical company. If you upset that AGPH is not at 70 on the first day of NOV, grow up. Why did you not predict the global stock mkt crash. Your little whinny statement would only have credibility if the mkt never had the last 2 weeks of panic and the world mkt were all at new highs as AGPH fell 10-15%. I would encourage somebody as impatient and ignorant of the global mkts to sell your AGPH shares because their are still many shorts that are looking for a way out.

To: JOHN W. who wrote (2594)	11/2/1997 4:56:00 PM
From: BarryH	Respond to of 6136

I think both of you might be right..the long term valuation of AGPH could be $2.5MM,it's sales,earnings and pipeline should put in that league but nearterm things could be dicy. This sector is subject to great swings because it is precieved as an unsafe haven. Just look at last April for proof of that. My own feeling is that there will be a flight for safety both within stocks and outside of them( to bonds). I'll continue to believe that as long as the yield curves and stock index move in the SAME direction as they did last week. THe price of AGPH is a question of timing and how rational vs emotional the traders are... Just my opinion.. BarryH